A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis

Trial Profile

A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Guselkumab (Primary) ; Caffeine; Dextromethorphan; Midazolam; Omeprazole; Warfarin
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 23 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 27 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 06 Jun 2016 Planned End Date changed from 1 Oct 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top